A few prior studies have documented the use of CD19‐positive MACS to evaluate B‐cell neoplasms, mostly CLL/SLL, in post‐therapy settings,10, 11 for determining prognostic markers,12 and characterizing the mutational landscapes of B‐cell neoplasms.13, 14. Here, CD19 is linked to B-cell neoplasm.